Venetoclax D8
| Product Name | Venetoclax D8 |
|---|---|
| Alternate Names | Venetoclax Stable Isotopes, Stable Isotopes of Venetoclax |
| CAT No. | CS-DS-00020 |
| CAS No. | 1257044-40-8 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 876.49 g/mol |
| Mol. For. | C₄₅H₄₂D₈ClN₇O₇S |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Venetoclax |
| Purity | 95% |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CC1(C)CC(C2=CC=C(Cl)C=C2)=C(CC1)CN3CCN(C4=CC(OC5=CN=C6C(C=CN6)=C5)=C(C(N[S](=O)(C7=CC([N](=O)=O)=C(NCC8C([2H])([2H])C([2H])([2H])OC([2H])([2H])C8([2H])[2H])C=C7)=O)=O)C=C4)CC3 |
| Canonical Smiles | CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C |
| InchIKey | LQBVNQSMGBZMKD-UHFFFAOYSA-N |
| Inchl | InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) |
| IUPAC | 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Venetoclax D8 is a specific deuterated form of Venetoclax, a medication used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Venetoclax D8 is a potent inhibitor of B-cell lymphoma 2 (BCL-2) protein, which is involved in the regulation of apoptosis or programmed cell death. By inhibiting BCL-2, Venetoclax D8 can help induce apoptosis in cancer cells, leading to their death.
Venetoclax D8 is typically administered orally, in tablet form, and is available in various dosages. The medication is generally prescribed by a healthcare professional and should be taken exactly as directed to achieve maximum efficacy and minimize side effects. Patients taking Venetoclax D8 should be closely monitored for any adverse reactions, as the medication may cause a range of side effects such as diarrhea, nausea, vomiting, fatigue, and fever.
Chemically, Venetoclax D8 is a deuterated version of Venetoclax, meaning that certain hydrogen atoms in the molecule have been replaced with their heavier isotope, deuterium. This modification can increase the potency and duration of the medication, as well as improve its safety profile. The chemical structure of Venetoclax D8 is similar to that of Venetoclax, with the addition of eight deuterium atoms. The molecular formula of Venetoclax D8 is C45H45D8N7O7S and its molecular weight is 902.09 g/mol.
Get an Instant Quote
Related Compounds
Venetoclax-d6 | Venetoclax D7 trifluoroacetate |